Christopher Jackson has substantial experience in products liability and Medicaid fraud litigation, patent litigation, complex commercial litigation, and international arbitration.  He has deep experience in the life sciences sector, including cases relating to product licensing, drug development, regulatory approvals, and marketing.  Chris has also handled trademark disputes and false advertising litigation as well as privacy law compliance in the context of cross-border litigation.  Prior to joining the firm, he practiced at Patterson Belknap Webb & Tyler LLP.

Chris is a graduate of Columbia Law School, where he was a James Kent scholar and a Harlan Fiske Stone Scholar.  He formerly served as Law Clerk to Hon.  Dickinson R. Debevoise of the U.S. District Court for the District of New Jersey.  Prior to attending law school, Chris received his M.A. in English and his B.A., summa cum laude, from Columbia University, He is also a former world ranked professional squash player and is proficient in French.

Christopher Jackson has substantial experience in products liability and Medicaid fraud litigation, patent litigation, complex commercial litigation, and international arbitration.  He has deep experience…

Education

Columbia Law School (J.D. 2000); Columbia University (M.A. 1985; B.A., summa cum laude, 1981)

Bar Admissions

New York State; New Jersey State; U.S. District Courts for the Southern and Eastern Districts of New York; U.S. District Court for the District of New Jersey

Activities and Affiliations

Member, New York City Bar Association

Former Member, Law360 Editorial Advisory Board (for Life Sciences Coverage)

Each year, Law360 selects a small group of practitioners from across the country in each of its practice area and industry groups to aid in shaping the publication’s editorial content for the following year. This year, five C&G attorneys were named as Law360 Editorial Advisory Board Members: 
 

- Mark S Cohen, Partner:  White Collar Advisory Board

- Robert J Gavigan, Partner: Mergers & Acquisitions Advisory Board

- Bonnie J Roe, Partner:  Private Equity Advisory Board

- Daniel H Tabak, Partner: Legal Ethics Advisory Board

- Christopher M P Jackson, Counsel: Life Sciences Advisory Board

 

This article discusses the Teva v. Sandoz decision and the tension it creates between the subordinate status afforded extrinsic evidence under Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) and the deference that will be afforded district court factual findings based on extrinsic evidence.  

This article outlines some considerations to keep in mind in identifying jurors who may be more or less receptive to common trial themes in health care industry cases.  Topics include juror attitudes toward industry and the medical profession, views of government and its role in health care, and more general personality traits and methodologies that may influence jurors’ analysis of key recurring issues. 

The article provides an analysis of recent remarks by Assistant Attorney General Stuart Delery, in which the AAG described the government’s approach to enforcement actions targeting off-label promotion of drugs and devices.  Considering the AAG’s remarks along with recent FDA draft guidance on the distribution of scientific literature, the article focuses on the effect that First Amendment concerns, intensified by recent case law developments, may have had on the way in which the government investigates cases, evaluates evidence, and develops and presents its theories of liability in off-label cases.

A discussion on emerging best practices for drafting arbitration clauses with class action waivers.